Ribociclib,Palbociclib,Letrozole
novartis,pfizer
['bcsm', 'improve ', 'paloma-2']
paloma-2: os update palbo+et did not significantly improve os compared to pbo+et is there a difference btw cdk4/6i interpret with caution given missing survival data and distinct cohort in this trial (22% w/dfi &lt;=12m) await harmonia study #asco2022 #bcsm 
Breast Medical Oncologist @UNC_Lineberger Prior @JCO_ASCO editorial fellow. Views are my own.